Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RTC-4202
- Development stage
- Preclinical
- Lead developer
- Ripple Therapeutics
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravitreal, Ophthalmic
01
Overview
RTC-4202 is a small molecule prodrug developed by Ripple Therapeutics for the treatment of dry age-related macular degeneration (AMD) and geographic atrophy (GA). Administered via intravitreal injection, the drug utilizes the proprietary Epidel platform, which engineers the active pharmaceutical ingredient into a prodrug that forms a solid, sustained-release implant without the use of polymers. RTC-4202 targets Complement Factor B (CFB), a critical component of the alternative complement pathway, aiming to reduce the progression of retinal degeneration by inhibiting complement-mediated inflammation and cell death.
- Other names
- RTC-4202-Ripple-CFBRTC4202-Ripple-CFBRTC 4202-Ripple-CFB
02
Targets
CFB (Complement Factor B)
Beyond the preview
Go deeper on RTC-4202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RTC-4202.